THLD MNTA AINV VHC RSO TORM DMND GMCR APKT AMSC
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who needs cash..in California u can bid in TSLA shares!
UVXY up nearly $3 p/m
what u talkin bout willis?
very nice..squeeze'em!
Applied Genetic Technologies looks to raise around $45M in IPO
Applied Genetic Technologies intends to sell 3.57M shares at a price of $13-15 in its Nasdaq IPO.
At $14, Applied Genetic would raise a net $44.8M.
The company, which develops gene therapy for inherited retinal disease, plans to trade under the ticker symbol "AGTC."
There's also a greenshoe option of 535,650 shares
http://www.sec.gov/Archives/edgar/data/1273636/000119312514094588/d615962ds1a.htm#toc615962_4
RTI Surgical up 18% premarket
Shares of RTI Surgical (RTIX) are poised for a gap up at the open. Investors appear to like the prospects of two new products launched today.
NanOss Bioactive 3D, a synthetic three dimensional bioscaffold that supports bone formation and map3 Cellular Allogeneic Bone Graft, an implant that generates and maintains new bone are now available for commercial sale.
Consensus EPS and revenue estimates for 2014 and 2015 are $0.07/share on revenues of $237M and $0.13/share on revenues of $268M, respectively.
162 mutual funds have positions, down from 197 a year earlier.
RTI Surgical up 18% premarket
Shares of RTI Surgical (RTIX) are poised for a gap up at the open. Investors appear to like the prospects of two new products launched today.
NanOss Bioactive 3D, a synthetic three dimensional bioscaffold that supports bone formation and map3 Cellular Allogeneic Bone Graft, an implant that generates and maintains new bone are now available for commercial sale.
Consensus EPS and revenue estimates for 2014 and 2015 are $0.07/share on revenues of $237M and $0.13/share on revenues of $268M, respectively.
162 mutual funds have positions, down from 197 a year earlier.
FDA approves the first migraine prevention device
FDA approves the first transcutaneous electrical nerve stimulation (TENS) device, made by the Belgian firm STX-Med, for the prevention of migraine headaches.
The product, called Cefaly, is battery operated and resembles a plastic headband worn across the forehead.
Cefaly is available by prescription to patients aged 18 years and older. It should be used only once per day for no more than 20 minutes.
Other FDA-approved products, such as TEVA's (TEVA) Zecuity, treat migraine symptoms.
Pfizer Prevanar 13 helps to almost halve certain type of pneumonia
Pfizer's (PFE) Prevanar 13 vaccine helped cause a 46% drop in incidents of vaccine-type community-acquired pneumonia (CAPP) in a massive trial of 85,000 patients aged 65 and older when compared with a placebo.
The "trial is the first in adults to clearly demonstrate a significant reduction in vaccine-type pneumococcal CAP," Pfizer said.
The company disclosed the figure when providing details of the study. The firm already said last month that Prevanar 13 met its primary and secondary goals
http://seekingalpha.com/pr/9237603-pfizer-presents-detailed-results-from-landmark-community-acquired-pneumonia-immunization-trial-in-adults-capita-evaluating-efficacy-of-prevenar-13
France probes Novartis, Roche for alleged antitrust practices
France's competition authority is investigating Novartis (NVS) and Roche over whether they conspired to prevent the use of Roche's (RHHBY) Avastin to treat vision problems in favor of the more expensive drug Lucentis, which the companies co-promote.
The news comes after Italy last week fined the firms a combined €182.5M over similar accusations.
http://www.bloomberg.com/news/2014-03-11/french-competition-regulator-probes-roche-novartis-on-avastin.html
PDL BioPharma ups guidance
PDL BioPharma (PDLI) increases its Q1 revenue guidance to $133M, up from the consensus estimate of $129M. This represents an increase of 45% from a year earlier.
The improved revenue outlook is due to increased product sales, higher royalty rates for certain products and a $5M retroactive payment from the Genentech settlement agreement.
not yet..wanna see more volume or 2.02,.which ever comes first,lol
Synta downgraded
Stifel downgrades Synta Pharmaceuticals (SNTA) from Hold to Sell.
Analyst Brian Klein cites delayed data readouts, changes in clinical trial designs, management changes and the need for additional capital as reasons for the change of outlook.
Zogenix's Zohydro faces ban following successful study of rival
Zogenix (ZGNX -11.9%) could face even stronger calls for its powerful painkiller Zohydro to be pulled from the market after privately held Purdue Pharma said its hydrocodone bitartrate treatment cut chronic lower-back pain in a Phase III trial.
Purdue's treatment is difficult to crush and snort or inject, while Zohydro doesn't have such features, which has led to wide-ranging calls for the FDA to drop its approval of the drug over fears that it will be abused.
The agency has already indicated that it could pull Zohydro if a rival drug with an "abuse-deterrent formulation" was created.
Following the late-stage study for hydrocodone bitartrate, Purdue intends to ask for an accelerated FDA review of the drug.
Zogenix is developing a tamper-resistant version of Zogenix, but it won't be available until the end of 2016.
http://www.purduepharma.com/news-media/2014/03/purdue-pharma-l-p-announces-positive-phase-3-clinical-trial-results-of-once-daily-hydrocodone-bitartrate-extended-release-tablets/
serf has cursed all his old plays,lol
SNTA,ZGNX,TEU droppers
TEU -13%
ZGNX -13%
SNTA -19%
SNTA -19%
HDY woodshed -58%
cool..HDY -58%..lol
lets bounce
PLUG unsucked a bit
little bounce to 1.82 and smacked back to 1.680
nah..only Herb is such a HERB..and he moved west too..hmmmm
thanks..quick analyst this morning..Piper Jaffray downgrades $GERN from Overweight to Neutral http://t.co/hakSJJdrJB
Read more: http://www.nasdaq.com/symbol/gern/stream#ixzz2vkWWMcFI
GERN -60% pre market ..1.66 low so far.. with $100M February raise I think they are barely trading above cash..overdone?
GERN earnings scheduled for this afternoon
tiny 1.78 to pay attention
GERN woodshed ..-60%..on fda hold news..tiny 1.78 for shiggles
and don't be cheap with da brownies!
think GERN has about 1.50 a share in cash,fwiw..they raised 100M a month ago
http://finviz.com/quote.ashx?t=gern
ewwww or yummy..we shall see
ADAM tried his best to quash LJPC yesterday too, wonder if he will try harder today..waiting on one of his.".my buy is short this pos because..and my buddy is never wrong pieces"..lol
lol
Good Morning, where Flo's? need some caffeine and Colorado brownies for breakfast!
twitter is like seeking alpha..could be a curse if already in a trade..but they provide plenty of tankers,lol
when will the power of CHU and Citron ( C&C) back off PLUG?
ok I am lazy..easier to post link than splain it ,lol